Status:
WITHDRAWN
Amikacin Penetration Into the Cerebrospinal Fluid
Lead Sponsor:
Rambam Health Care Campus
Conditions:
Gram Negative Meningitis
Post Traumatic Bacterial Meningitis
Eligibility:
All Genders
18-75 years
Phase:
PHASE4
Brief Summary
The limited available data precludes establishing an antibiotic regimen in patients suffering from bacterial meningitis after head trauma, or spontaneous bleeding Understanding the disposition of Amik...
Detailed Description
The limited available data precludes establishing an antibiotic regimen in patients suffering from bacterial meningitis after head trauma, or spontaneous bleeding Understanding the disposition of Amik...
Eligibility Criteria
Inclusion
- Culture proved bacterial meningitis where the prescribed therapy includes the use of systemic and intraventricular amikacin therapy.
- The included patient should have an intraventricular catheter placed for intraventricular pressure measurement and admitted to an intensive care unit.
- Blood creatinine concentration up to 1.49 mg/dL measured at the inclusion day.
Exclusion
- Patients or legal guardians who refuse to participate in the study.
- Known allergy to amikacin.
- Blood creatinine concentration of 1.5 mg/dL or higher.
- Subjects without intraventricular catheter who will need repeated lumbar punctures for CSF amikacin determinations.
- Patients suffering from known chronic liver disease.
Key Trial Info
Start Date :
September 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2008
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00362245
Start Date
September 1 2006
End Date
November 1 2008
Last Update
November 3 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rambam Health Care Campus
Haifa, Israel, 31096